Remove 2011 Remove Immunity Remove Immunization
article thumbnail

SAEM Clinical Images Series: Not Your Average Ear Infection

ALiEM - Pharm Pearls

A 5-year-old generally healthy fully immunized boy presented to the ED with worsening left ear redness, swelling, and tenderness that his family noticed the day before presentation. 2011 Jan;13(1):21-4. His family had also recently noticed an abrasion over that ear. Treat this condition with anti-pseudomonal antibiotics.

article thumbnail

The future of AI drug discovery & development in immunology and GPCR research

pharmaphorum

A mere six months ago Verily launched the study with Sosei Heptares – a global leader in GPCR structure-based drug design – with an aim to “prioritise protein targets for therapeutic targeting in immune-mediated disease”. Verily’s Immune Profiler can, Kim asserted, “generate more than 8 million immune measures across 24 immune cell subsets”.

Immunity 135
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

SAEM Clinical Images Series: Not Your Average Eczema

ALiEM - Pharm Pearls

He is up to date on childhood immunizations and is not prescribed any oral medications. 2011 Feb;40(2):167-9. Mom had been applying Aquaphor and Vaseline several times a day. On the day of presentation, he woke up with a new rash over his face and hands which prompted the ED visit. Studdiford JS, Valko GP, Belin LJ, Stonehouse AR.

Immunity 130
article thumbnail

Early cell therapy successes start to turn the tide in lupus

Pharmaceutical Technology

In August 2021, Saphnelo, a type 1 interferon receptor antibody, became the first lupus treatment to be approved since GSK’s Benlyta (belimumab) won a regulatory nod in 2011. In lupus, the body’s immune system starts to attack its own cells. As per AstraZeneca's recent Q3 earnings, Saphnelo has yielded $69 million to date this year.

Immunity 144
article thumbnail

Re-engineering proteins to develop novel immunotherapies

European Pharmaceutical Review

The field of immunotherapy is constantly evolving with the ultimate goal to develop new treatments that help the body’s immune system fight cancer. Immune cells, such as T cells and natural killer (NK) cells, have the inherent ability to combat diseases, including cancer, but are often inhibited by the body’s own suppressive mechanisms.

article thumbnail

Phase 3 trial data confirm efficacy and safety profile of R21/Matrix-M malaria vaccine in African children

Express Pharma

The R21/Matrix-M vaccine was designed in 2011 as a potential improvement on the RTS, S/AS01 malaria vaccine designed in the 1980s. A phase II trial in Burkina Faso, reporting in 2021, was the first to show that R21/Matrix-M could reach the WHO-specified target of 75 per cent efficacy in African children.

Vaccines 105
article thumbnail

Paving the way for anti-Abeta active immunotherapy

European Pharmaceutical Review

The vaccination of patients with AN1792 led to the activation of their immune systems, which started producing endogenous anti-Abeta antibodies. Therefore, active immunotherapy to trigger the immune system to produce sustained levels of endogenous antibodies has now become far more attractive.